Ponesimod, a selective S1P1 receptor modulator: A potential treatment for multiple sclerosis and other immune-mediated diseases

Therapeutic Advances in Chronic Disease

Volumn 7, Issue 1, 2016, Pages 18-33

  D’ambrosio, Daniele ^a   Freedman, Mark S ^b   Prinz, Joerg ^c  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF OTTAWA   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autoimmune Disease; Lymphocyte Migration; Multiple Sclerosis; Psoriasis; Transplantation

Indexed keywords

FINGOLIMOD; PLACEBO; PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

AREA UNDER THE CURVE; COUGHING; DIZZINESS; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOPATHOLOGY; INFLUENZA; INSOMNIA; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QTC INTERVAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

EID: 84953439191     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315617354     Document Type: Review

References (59)

1. Bana e Costa C. Vansnick J. (1999) The Macbeth approach: basic ideas, software and an application. In: Ed. Meskens N. Roubens M. (eds), Advances in Decision Analysis. Dordrecht: Kluwer Academic Publishers, pp. 131–157.
2. Bolli M. Abele S. Binkert C. Bravo R. Buchmann S. Bur D. et al. (2010) 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 53: 4198–4211.
3. Brinkmann V. (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84–105.
4. Brossard P. Derendorf H. Xu J. Maatouk H. Halabi A. Dingemanse J. (2013) Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 76: 888–896.
5. Brossard P. Scherz M. Halabi A. Maatouk H. Krause A. Dingemanse J. (2014) Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 54: 179–188.
6. Camm J. Hla T. Bakshi R. Brinkmann V. (2014) Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J 168: 632–644.
7. Choi J. Gardell S. Herr D. Rivera R. Lee C. Noguchi K. et al. (2011) FTY 720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108: 751–756.
8. Chun J. Hla T. Lynch K. Spiegel S. Moolenaar W. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 62: 579–587.
9. Claes N. Dhaeze T. Fraussen J. Broux B. van Wijmeersch B. Stinissen P. et al. (2014) Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PloS ONE 9: e111115.
10. Cyster J. Schwab S. (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30: 69–94.
11. D'Ambrosio D. Steinmann J. Brossard P. Dingemanse J. (2015) Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol 37: 103–109.
12. Dev K. Mullershausen F. Mattes H. Kuhn R. Bilbe G. Hoyer D. et al. (2008) Brain sphingosine-1-phosphate receptors: implication for FTY 720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77–93.
13. Diluvio L. Vollmer S. Besgen P. Ellwart J. Chimenti S. Prinz J. (2006) Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 176: 7104–7111.
14. Foster C. Howard L. Schweitzer A. Persohn E. Hiestand P. Balatoni B. et al. (2007) Brain penetration of the oral immunomodulatory drug FTY 720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469–475.
15. Freedman M. (2013) Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chronic Dis 4: 192–205.
16. Gaide O. Emerson R. Jiang X. Gulati N. Nizza S. Desmarais C. et al. (2015) Common clonal origin of central and resident memory T cells following skin immunization. Nat Med 21: 647–653.
17. Gonzalez-Cabrera P. Brown S. Studer S. Rosen H. (2014) S1P signaling: new therapies and opportunities. F1000Prime Rep 6: 109.
18. Grigorova I. Schwab S. Phan T. Pham T. Okada T. Cyster J. (2009) Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells. Nat Immunol 10: 58–65.
19. Hla T. Brinkmann V. (2011) Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 76: S3–S8.
20. Hoch M. D'Ambrosio D. Wilbraham D. Brossard P. Dingemanse J. (2014) Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci 63: 147–153.
21. Hoch M. Darpo B. Brossard P. Zhou M. Stoltz R. Dingemanse J. (2015 a) Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals. Basic Clin Pharmacol Toxicol 116: 429–437.
22. Hoch M. Vaclavkova A. Krause A. Strong A. Bush J. Dingemanse J. et al. (2015 b) A novel gradual up-titration regimen mitigates the first-dose effects of ponesimod, a selective S1P1 receptor modulator. Clin Ther 37: e36–e37.
23. Hu W. Mahavadi S. Huang J. Li F. Murthy K. (2006) Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection. Am J Physiol Gastrointest Liver Physiol 291: G605–G610.
24. Hudgens S. Schüler R. Hunsche E. Leist T. (2015) Measurement confirmation of the fatigue symptoms and impacts questionnaire – relapsing multiple sclerosis (FSIQ RMS). Value Health 18: A26.
25. Huu D. Matsushita T. Jin G. Hamaguchi Y. Hasegawa M. Takehara K. et al. (2013) FTY 720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum 65: 1624–1635.
26. Kappos L. Antel J. Comi G. Montalban X. O'Connor P. Polman C. et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124–1140.
27. Kappos L. Radue E. O'Connor P. Polman C. Hohlfeld R. Calabresi P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
28. Kavanaugh A. Mease P. Gomez-Reino J. Adebajo A. Wollenhaupt J. Gladman D. et al. (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73: 1020–1026.
29. Koyrakh L. Roman M. Brinkmann V. Wickman K. (2005) The heart rate decrease caused by acute FTY 720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 5: 529–536.
30. Krause A. Brossard P. D'Ambrosio D. Dingemanse J. (2014) Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn 41: 261–278.
31. Lee S. Flowers M. (2008) Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008: 134-141.
32. Lorenz J. Arend L. Robitz R. Paul R. Maclennan A. (2007) Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol Regul Integr Comp Physiol 292: R440–R446.
33. Lublin F. Miller D. Freedman M. Cree B. Wolinsky J. Weiner H. (2015) Oral fingolimod versus placebo in primary progressive multiple sclerosis: results of a large phase III, randomised trial. Lancet, in press.
34. Martin P. Inamoto Y. Carpenter P. Lee S. Flowers M. (2011) Treatment of chronic graft-versus-host disease: past, present and future. Korean J Hematol 46: 153–163.
35. Mehling M. Brinkmann V. Antel J. Bar-Or A. Goebels N. Vedrine C. et al. (2008) FTY 720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71: 1261–1267.
36. Mehling M. Johnson T. Antel J. Kappos L. Bar-Or A. (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76: S20–S27.
37. Nakamura M. Matsuoka T. Chihara N. Miyake S. Sato W. Araki M. et al. (2014) Differential effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler 20: 1371–1380.
38. Novartis (2015) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf (accessed 4 August 2015).
39. O'Connor P. Lublin F. Wolinsky J. Confavreux C. Comi G. Freedman M. et al. (2013) Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol 260: 2472–2480.
40. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. Olsson T. et al. (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365: 1293–1303.
41. Olsson T. Boster A. Fernandez O. Freedman M. Pozzilli C. Bach D. et al. (2014) Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 85: 1198–1208.
42. Papp K. Reich K. Leonardi C. Kircik L. Chimenti S. Langley R. et al. (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 73: 37–49.
43. Peters S. Alewijnse A. (2007) Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 7: 186–192.
44. Piali L. Froidevaux S. Hess P. Nayler O. Bolli M. Schlosser E. et al. (2011) The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 337: 547–556.
45. Pinschewer D. Brinkmann V. Merkler D. (2011) Impact of sphingosine 1-phosphate modulation on immune outcomes. Neurology 76: S15–S19.
46. Pozzilli C. Fernandez O. Olsson T. Freedman M.S. Melanson M. Boster A. et al. (2013) Maintenance of efficacy, safety and tolerability of ponesimod in patients with relapsing remitting multiple sclerosis: phase II extension study. Poster presentation at ECTRIMS (2013) European Committee for Treatment & Research in Multiple Sclerosis, 29th Congress, 2–5 October, Copenhagen, Denmark.
47. Rey M. Hess P. Clozel M. Delahaye S. Gatfield J. Nayler O. et al. (2013) Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator. PloS ONE 8: e74285.
48. Reyes M. Brossard P. Chassard D. Hoch M. Dingemanse J. (2014 a) Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol 70: 287–293.
49. Reyes M. Hoch M. Brossard P. Dingemanse J. (2014 b) Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology 94: 223–229.
50. Reyes M. Hoch M. Brossard P. Wagner-Redeker W. Miraval T. Dingemanse J. (2015) Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans. Xenobiotica 45: 139–149.
51. Salomone S. Yoshimura S. Reuter U. Foley M. Thomas S. Moskowitz M. et al. (2003) S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 469: 125–134.
52. Scherz M. Brossard P. D’ Ambrosio D. Ipek M. Dingemanse J. (2015) Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects. J Clin Pharmacol 55: 688–697.
53. Sobel K. Menyhart K. Killer N. Renault B. Bauer Y. Studer R. et al. (2013) Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and smad-independent signaling. J Biol Chem 288: 14839–14851.
54. Subei A. Cohen J. (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29: 565–575.
55. Vaclavkova A. Chimenti S. Arenberger P. Hollo P. Sator P. Burcklen M. et al. (2014) Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 384: 2036–2045.
56. Watterson K. Ratz P. Spiegel S. (2005) The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal 17: 289–298.
57. Wilson L. Loucks A. Bui C. Gipson G. Zhong L. Schwartzburg A. et al. (2014) Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci 344: 80–87.
58. Wolff D. Schleuning M. von Harsdorf S. Bacher U. Gerbitz A. Stadler M. et al. (2011) Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 17: 1–17.
59. You S. Piali L. Kuhn C. Steiner B. Sauvaget V. Valette F. et al. (2013) Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PloS ONE 8: e77296.